文献速递重症综合管理与镇静镇痛消化、代谢与肾脏急症

血液系统恶性肿瘤合并多器官衰竭入住ICU患者的长期结局

Long-Term Outcome of Patients With a Hematologic Malignancy and Multiple Organ Failure Admitted at the Intensive Care.
PubMed 文献 · Crit Care Med · 2019-01-01
一句话结论血液系统恶性肿瘤合并多器官衰竭患者1年生存率为38%,多器官衰竭不应作为拒绝ICU收治的标准(作者认为)。

这项回顾性队列研究纳入荷兰5所大学医院的1097例血液系统恶性肿瘤ICU患者,随访至少1年,主要终点为1年生存率。结果显示1年生存率为38%,多器官衰竭与长期生存呈负相关,无呼吸衰竭是1年生存的最强预测因素。2、3、4个器官衰竭患者的生存率分别为27%、22%、8%。在可获得WHO体能评分的存活患者中,39%在ICU出院3个月后WHO体能评分为0-1分。作者认为多器官衰竭不应作为排除此类患者入住ICU的标准。

要点

  • 血液系统恶性肿瘤合并多器官衰竭患者1年生存率为38%,多器官衰竭不应作为拒绝ICU收治的标准(作者认为)。
  • 2、3、4个器官衰竭患者的1年生存率分别为27%、22%、8%,器官衰竭数目越多生存率越低。
  • 无呼吸衰竭是1年生存的最强预测因素。
  • 在可获得WHO体能评分的存活患者中,39%在ICU出院3个月后WHO体能评分为0-1分。
  • 功能结局与衰竭器官数目无关。

适用人群与场景

  • 荷兰5所大学医院ICU收治的1097例血液系统恶性肿瘤患者。
  • 多器官衰竭定义为2个或以上器官衰竭,器官衰竭包括急性肾损伤、呼吸衰竭、肝衰竭和血流动力学衰竭。

诊断标准与关键阈值

  • 多器官衰竭定义为2个或以上器官衰竭;器官衰竭分类为急性肾损伤、呼吸衰竭、肝衰竭和血流动力学衰竭。
  • 功能结局采用ICU出院后3个月的WHO体能评分评估。

研究设计与关键结果

  • 回顾性队列研究,纳入荷兰5所大学医院的1097例血液系统恶性肿瘤ICU患者,随访至少1年。
  • 主要终点1年生存率为38%。
  • 多器官衰竭与长期生存呈负相关;无呼吸衰竭是1年生存的最强预测因素。
  • 2、3、4个器官衰竭患者的1年生存率分别为27%、22%、8%。
  • 在可获得WHO体能评分的存活患者中,39%在ICU出院3个月后WHO体能评分为0-1分;功能结局与衰竭器官数目无关。

证据类型、等级与局限

  • 证据类型:回顾性队列研究(HEMA-ICU研究组的一部分)。
  • 局限:原文未报告局限性。

对床旁实践的改变

  • 作者认为多器官衰竭不应作为排除血液系统恶性肿瘤患者入住ICU的标准。
  • 原文未据此给出其他推荐。

提炼说明

  • 本条依据论文摘要整理;摘要未涉及「处置流程与药物剂量」「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开

OBJECTIVES: Historically, patients with a hematologic malignancy have one of the highest mortality rates among cancer patients admitted to the ICU. Therefore, physicians are often reluctant to admit these patients to the ICU. The aim of our study was to examine the survival of patients who have a hematologic malignancy and multiple organ failure admitted to the ICU.

DESIGN: This retrospective cohort study, part of the HEMA-ICU study group, was designed to study the survival of patients with a hematologic malignancy and organ failure after admission to the ICU. Patients were followed for at least 1 year.

SETTING: Five university hospitals in the Netherlands.

PATIENTS: One-thousand ninety-seven patients with a hematologic malignancy who were admitted at the ICU.

INTERVENTIONS: None.

MEASUREMENTS AND MAIN RESULTS: Primary outcome was 1-year survival. Organ failure was categorized as acute kidney injury, respiratory failure, hepatic failure, and hemodynamic failure; multiple organ failure was defined as failure of two or more organs. The World Health Organization performance score measured 3 months after discharge from the ICU was used as a measure of functional outcome. The 1-year survival rate among these patients was 38%. Multiple organ failure was inversely associated with long-term survival, and an absence of respiratory failure was the strongest predictor of 1-year survival. The survival rate among patients with 2, 3, and 4 failing organs was 27%, 22%, and 8%, respectively. Among all surviving patients for which World Health Organization scores were available, 39% had a World Health Organization performance score of 0-1 3 months after ICU discharge. Functional outcome was not associated with the number of failing organs.

CONCLUSIONS: Our results suggest that multiple organ failure should not be used as a criterion for excluding a patient with a hematologic malignancy from admission to the ICU.

来源:Crit Care Med,查看原文。版权归原作者所有。

参考来源

  1. de Vries VA, Müller MCA, Arbous MS, et al. Long-Term Outcome of Patients With a Hematologic Malignancy and Multiple Organ Failure Admitted at the Intensive Care. Crit Care Med. 2019. PMID: 30335623. doi:10.1097/CCM.0000000000003526

供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。